1. Lou, Yichao, Chen, Desheng, Gu, Qi, Zhu, Qi, Sun, Hongcheng. 2024. PANoptosis-related molecule CASP2 affects the immune microenvironment and immunotherapy response of hepatocellular carcinoma. In Heliyon, 10, e27302. doi:10.1016/j.heliyon.2024.e27302. https://pubmed.ncbi.nlm.nih.gov/38509889/
2. Tiwari, Meenakshi, Sharma, Lokendra K, Vanegas, Difernando, Lechleiter, James D, Herman, Brian. . A nonapoptotic role for CASP2/caspase 2: modulation of autophagy. In Autophagy, 10, 1054-70. doi:10.4161/auto.28528. https://pubmed.ncbi.nlm.nih.gov/24879153/
3. Cai, Xintong, Lin, Jie, Liu, Li, Ji, Liyan, Sun, Yang. 2024. A novel TCGA-validated programmed cell-death-related signature of ovarian cancer. In BMC cancer, 24, 515. doi:10.1186/s12885-024-12245-2. https://pubmed.ncbi.nlm.nih.gov/38654239/
4. Uctepe, Eyyup, Vona, Barbara, Esen, Fatma Nisa, Maroofian, Reza, Yesilyurt, Ahmet. 2023. Bi-allelic truncating variants in CASP2 underlie a neurodevelopmental disorder with lissencephaly. In European journal of human genetics : EJHG, 32, 52-60. doi:10.1038/s41431-023-01461-2. https://pubmed.ncbi.nlm.nih.gov/37880421/
5. Zhang, Qiao, Li, Yan, Zhao, Mei, Zhong, Jialing, Huang, Changzhi. 2019. MiR-494 acts as a tumor promoter by targeting CASP2 in non-small cell lung cancer. In Scientific reports, 9, 3008. doi:10.1038/s41598-019-39453-2. https://pubmed.ncbi.nlm.nih.gov/30816202/